Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Addex and Indivior intend to accelerate additional GABA-B PAM compounds for addiction

Feb. 14, 2019

Antidote Therapeutics to collaborate with NCI on development of ATI-1013

Feb. 8, 2019

Phase Ib data support expansion of indication for BioXcel's BXCL-501

Feb. 5, 2019

Phase II data for PF-04457845 as potential treatment of cannabis withdrawal and dependence

Jan. 15, 2019

Nanoscavenger versus neurotoxins

Jan. 7, 2019

ITI-333 shows promise for the treatment of pain and substance abuse-derived disorders

Dec. 24, 2018

Adial engages CRO to oversee phase III trial of AD-04 for alcohol use disorder

Nov. 23, 2018

Weekly and monthly Buvidal approved in Europe for opioid dependence

Nov. 23, 2018

Blocking BigLEN-GRP171 signaling reduces opioid addiction and withdrawal in mice

Nov. 15, 2018

KemPharm adds drug for stimulant use disorder to pipeline

Nov. 15, 2018

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...